Summary
Cardinal Health, Inc. reported revenue of $21.97 billion for the three months ended September 30, 2007, a 5% increase year-over-year, driven by pharmaceutical price appreciation, increased volume, and acquisitions. While revenue grew, operating earnings saw a more substantial 9% increase to $489.8 million, benefiting from a strong gross margin expansion. Net earnings rose 11% to $301.8 million, with diluted EPS reaching $0.82, a significant increase from the prior year, partly due to a lower share count from robust share repurchases. The company continues to manage significant restructuring and integration costs, which totaled $22.5 million in special items for the quarter. Additionally, Cardinal Health reached significant legal settlements, including a $600 million settlement for federal securities litigation and a $40 million settlement for ERISA litigation, aimed at resolving past uncertainties. The company's balance sheet shows total assets of $22.99 billion and total shareholders' equity of $7.07 billion, with substantial share repurchases continuing to reduce outstanding shares.
Key Highlights
- 1Revenue increased by 5% to $21.97 billion for the quarter, driven by pharmaceutical price appreciation and volume growth.
- 2Operating earnings grew by 9% to $489.8 million, reflecting improved gross margins that more than offset higher SG&A expenses.
- 3Net earnings increased by 11% to $301.8 million, and diluted EPS rose to $0.82.
- 4The company repurchased approximately $675 million of its common stock during the quarter under its ongoing share repurchase programs.
- 5Significant legal settlements were reached, including a $600 million settlement for federal securities litigation and a $40 million settlement for ERISA litigation.
- 6Special items, including restructuring and acquisition integration charges, totaled $22.5 million for the quarter.
- 7The adoption of FIN No. 48 resulted in a $139.3 million reduction in retained earnings due to unrecognized tax benefits.